Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease
- 9 June 2016
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 82 (2) , 352-361
Abstract
Aim: The aim of the study was to assess ticagrelor's effects on inhibition of platelet aggregation (IPA), P2Y12 reaction units (PRU, measure of platelet P2Y12 receptor blockade), pharmacokinetic (PK) parameters and safety in Chinese patients with stable coronary artery disease (CAD).Methods: This was an open label, single centre, randomized study. Thirty‐six patients on low dose aspirin (75–100 mg day–1) received ticagrelor 45, 60 or 90 mg (single dose, days 1 and 7; twice daily, days 3–6). IPA (final extent), PRU and ticagrelor and AR‐C124910XX plasma concentrations were determined.Results: On day 1, peak IPA >80% occurred 2–6 h post‐dose (all doses). PRU was markedly reduced at 1 h vs. baseline (all doses). With ticagrelor 45 and 90 mg twice daily, maximum IPA (mean, SD) was 91% (13%), and 99% (3%), and maximum PRU reduction from baseline (mean, SD) was 82% (17%) and 92% (9%), respectively. Approximate dose‐proportional increases (mean [%CV]; 45 vs. 90 mg twice daily) in ticagrelor Cmax (616 [37] vs. 1273 [43] ng ml–1) and AUC (3882 [42] vs. 8206 [51] ng ml–1 h) and AR‐C124910XX parameters were seen. Pharmacodynamic and PK differences between 45 and 60 mg were small. No safety issues were identified.Conclusions: In Chinese patients with CAD, ticagrelor (45, 60 and 90 mg) markedly reduced platelet aggregation. The IPA and PRU magnitude increased generally with increasing doses. However, the mean pharmacodynamic differences between 45 and 60 mg doses were small. Following single and multiple doses, the mean Cmax and AUC values of ticagrelor and AR‐C124910XX increased approximately dose proportionally between 45 and 90 mg doses.Keywords
This publication has 32 references indexed in Scilit:
- Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An UpdateClinical Pharmacokinetics, 2015
- Platelet function tests: a comparative reviewVascular Health and Risk Management, 2015
- Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsPharmacogenomics and Personalized Medicine, 2015
- Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1Journal of Cardiovascular Pharmacology and Therapeutics, 2014
- Pharmacokinetics and Tolerability of Single and Multiple Doses of Ticagrelor in Healthy Chinese SubjectsClinical Drug Investigation, 2012
- Cytochrome P450 variations in different ethnic populationsExpert Opinion on Drug Metabolism & Toxicology, 2012
- Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow® assay? Role of haematocrit and haemoglobin levelsThrombosis and Haemostasis, 2011
- Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregationJournal of Thrombosis and Haemostasis, 2009
- Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary SyndromeJACC, 2007
- Systematic Screening for Polymorphisms in theCYP3A4Gene in the Chinese PopulationPharmacogenomics, 2006